Emmaus Life Sciences Announces its Common Stock to Begin Trading on OTCQB September 26

TORRANCE, Calif., Sept. 26, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it is approved to have its common stock trade on the OTCQB marketplace, effective September 26, 2019. The common stock of Emmaus was previously quoted on OTC Link® as OTC Pink.

“Trading on OTCQB is an important next step for Emmaus in moving to a major exchange,” stated Jay Sherwood, Chief Financial Officer of Emmaus. “The OTCQB requires increased reporting standards by its issuers and provides greater transparency and visibility of trade data, news and disclosures to the investment community, as well as offers convenient trading with real-time quotes through more broker dealers. Trading on the OTCQB will afford Emmaus with exposure to a quality tier of investors and the potential to further enhance liquidity for its shareholders.”

About Sickle Cell Disease
Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to organ damage, stroke, pulmonary complications, skin ulceration, infection and a variety of other adverse outcomes. Sickle cell disease is a significant unmet medical need, affecting approximately one hundred thousand patients in the U.S. and millions worldwide, the majority of which are of African descent. An estimated 1-in-365 African-American children is born with sickle cell disease.

About Endari®
Indication
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Important Safety Information
The most common adverse reactions in clinical studies include constipation, nausea, headache, and abdominal pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari at: http://www.ENDARIrx.com/PI.

About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. For more information, please visit www.emmauslifesciences.com.

Forward-looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update forward-looking statements. Factors previously disclosed in Emmaus’ reports filed with the Securities and Exchange Commission, among others, could cause actual results to differ materially from forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/emmaus-life-sciences-announces-its-common-stock-to-begin-trading-on-otcqb-september-26-300925793.html

SOURCE Emmaus Life Sciences, Inc.

Company Codes: OTC-PINK:EMMA, OTC-QB:EMMA